Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DBVT vs EVMN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EVMN Captures Overall Composite Edge (30.0 SELL vs 30.9 SELL), While DBVT Leads 3–2 on Growth & Valuation Pillars

EVMN Overall Winner 6-Pillar Tally: DBVT 3 – 2 EVMN (1 Tie) Matrix Metrics: DBVT 4 – 3 EVMN

As of Nov 16, 2026, Evommune, Inc. (EVMN) captures the overall head-to-head institutional edge over DBV Technologies S.A. (DBVT) on higher Unified Composite conviction (30.0/100 SELL vs. 30.9/100 SELL) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while DBVT wins 3–2 across the 6-pillar growth and valuation breakdown. DBVT trades at $10.27 (N/M Forward P/E, -5577.0% operating margin) versus EVMN at $7.10 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While DBVT currently prints a higher short-term Unified Composite Score (30.9/100 SELL vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -5577.0% operating margin) and revenue trajectory (+0.0% vs. -42.9% YoY).
  • Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both DBVT (30.9/100 SELL) and EVMN (30.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DBVT vs EVMN
DBVT NASDAQ
DBV Technologies S.A.
Biological Products, (No Disgnostic Substances)
$10.27
-6.76% 1D
Market Cap $692.2M
TTM Revenue $3.7M
Forward P/E N/M
Beta / 30D Vol 1.18β · 77% Vol
Unified Composite Score
30.9 / 100 SELL
Tech 15.0 Fund 36.0 Flow 60.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.9 · SMA20: $10.28 · SMA50: $10.78
EVMN US Equity Head-to-Head Winner
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47

6-Pillar Scorecard Institutional Category Breakdown (DBVT 3 – 2 EVMN)

Columns: Metric · DBVT · EVMN
1. Valuation Multiples DBVT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 142.9x N/M
2. Growth & Scale DBVT
Revenue Growth (YoY) -42.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.7M N/A
Market Cap $692.2M $315.5M
3. Profitability & Quality EVMN
Gross Margin 100.0% N/A
Operating Margin -5577.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -205.8% -69.5%
4. Balance Sheet & Cash Flow DBVT
Cash Generation (TTM) -$192M -$75M
Cash Flow Margin N/A N/A
Net Cash / Leverage $158M Net Cash $52M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase SURGE SURGE
Current IV / %ile 64.5% (13th %ile) 209.0% (53rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DBVT (4) vs EVMN (3)
Institutional Metric DBVT EVMN Criterion Row Edge
Market Capitalization
Scale
$692.2M $315.5M Larger Scale DBVT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-42.9% +0.0% Higher Growth EVMN
Operating Margin (TTM)
Profitability
-5577.0% 0.0% Higher Margin EVMN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-205.8% -69.5% Higher ROE EVMN
52-Week Range Position
Momentum
9% ($9–$26) 8% ($5–$33) Stronger Trend DBVT
Beta / 30D Volatility
Risk Regime
1.18β · 77% Vol 1.05β · 118% Vol Lower Realized Risk DBVT
Unified Institutional Score
Composite Signal
30.9 / 100 (SELL) 30.0 / 100 (SELL) Higher Composite DBVT
Trailing 12M Revenue (USD)
Operating Scale
$3.7M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 142.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$192M ($158M Net Cash) -$75M ($52M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +23.85 pp
DBVT: +13.48% · EVMN: +37.33%
3M Horizon DBVT +21.04 pp
DBVT: -29.03% · EVMN: -50.07%
6M Horizon DBVT +22.34 pp
DBVT: -45.23% · EVMN: -67.57%
1Y Horizon DBVT +39.67 pp
DBVT: -21.36% · EVMN: -61.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DBVT Revenue EVMN Revenue DBVT Op. Margin EVMN Op. Margin Margin Leader
FY2019 $10M N/A -1162.8% N/A DBVT
FY2020 $10M N/A -1408.7% N/A DBVT
FY2021 $10M N/A -1727.6% N/A DBVT
FY2022 $0M N/A -1994.9% N/A DBVT
FY2023 $20M N/A -486.0% N/A DBVT
FY2024 $0M $10M -2808.7% -1000.2% EVMN
FY2025 $10M $10M -2609.2% -623.6% EVMN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DBVT SURGE
5d in phase · OBV ACCUMULATION
Current IV 64.5%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DBVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DBVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.2M market capitalization and -5577.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DBVT vs EVMN Key Questions & Quantitative Answers

As of Nov 16, 2026, Evommune, Inc. (EVMN) captures the overall head-to-head institutional edge over DBV Technologies S.A. (DBVT) on higher Unified Composite conviction (30.0/100 SELL vs. 30.9/100 SELL) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while DBVT wins 3–2 across the 6-pillar growth and valuation breakdown. DBVT trades at $10.27 (N/M Forward P/E, -5577.0% operating margin) versus EVMN at $7.10 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DBVT currently prints a higher short-term Unified Composite Score (30.9/100 SELL vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -5577.0% operating margin) and revenue trajectory (+0.0% vs. -42.9% YoY). Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both DBVT (30.9/100 SELL) and EVMN (30.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

DBVT leads the Growth & Scale pillar: DBVT posts -42.9% YoY revenue growth and +0.0% YoY earnings growth on $3.7M TTM revenue (100.0% gross margin, -5577.0% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), DBVT cumulative revenue shifted +0.0% while EVMN shifted +0.0%. In operating R&D and SG&A reinvestment, DBVT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.

DBVT screens cheaper on headline valuation multiples. DBVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 142.9x EV/Revenue (unreported FCF margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DBVT (-205.8% ROE) versus EVMN (-69.5% ROE) capital efficiency.

In options market volatility and institutional positioning, DBVT carries 64.5% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.18β · 77% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.